Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Up 94.5% in March

Posted by Chris Copeland on Mar 30th, 2025

Kazia Therapeutics Limited (NASDAQ:KZIA – Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 115,900 shares, a growth of 94.5% from the February 28th total of 59,600 shares. Based on an average daily trading volume, of 1,850,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.3% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Maxim Group began coverage on Kazia Therapeutics in a report on Thursday, February 6th. They set a “buy” rating and a $3.00 price target for the company.

View Our Latest Research Report on KZIA

Kazia Therapeutics Trading Down 7.4 %

Shares of NASDAQ KZIA traded down $0.07 during midday trading on Friday, hitting $0.88. 69,902 shares of the stock traded hands, compared to its average volume of 852,788. Kazia Therapeutics has a one year low of $0.76 and a one year high of $15.80. The business has a 50 day moving average price of $1.09 and a two-hundred day moving average price of $3.00.

Institutional Trading of Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Barclays PLC purchased a new stake in shares of Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 120,000 shares of the company’s stock, valued at approximately $212,000. Barclays PLC owned 2.38% of Kazia Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Company Profile

(Get Free Report)

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.